Technical Title: Image-Guided Hypofractionated Radiotherapy with Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer
Advanced non-small cell lung cancer has a poor outcome with standard of care chemotherapy and radiation therapy (7 weeks). This is a study to test the safety and efficacy of a new schedule of radiation therapy and chemotherapy. Our goal is to improve patient outcomes through a new clinical trial using a more aggressive, compact (3 weeks) schedule of chemotherapy and radiation therapy where we give more daily radiation than standard of care, thoughtfully. We are able to do this at UCLA given our vast clinical experience in hypofractionated (shorter course) radiotherapy, our advanced treatment machines, our superb treatment team, and our expertise in using daily state-of-the-art real-time imaging to customize and individualize the radiation therapy for each patient. Our goal is to improve your outcome while living with advanced non-small cell lung cancer. However, this new schedule of radiation and chemotherapy is experimental with no guarantee that it will benefit individual subjects. To learn about clinical trials using this type of treatment, contact:
The investigator will design a treatment plan following a PET/CT planning scan consisting of 15 radiation treatment sessions, each taking less than one hour. Standard chemotherapy treatment may be administered, during, and 14 days after treatment.
A three month post radiotherapy and an annual PET-CT scan will be required to monitor your progress. CT scans will be every three months when there is no scheduled PET-CT. Blood tests will be required 4 – 6 weeks post radiotherapy, and then every three months for the first two years.